Unfortunately #CLL patients have a higher risk of contracting skin cancer... but Australian scientists are developing a Melanoma blood test: Scientists unveil 'world-first' research | via BBC News (UK) ow.ly/PNyB30l0dKo... See MoreSee Less
#CLL expert Prof. John Gribben discusses the different treatment options available for the treatment of high-risk CLL and how Allogenic stem cell transplantation fits into the treatment algorithm in the era of novel agents | via ASH www.bloodjournal.org/content/132/1/31/... See MoreSee Less
Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibruti...
Top oncologist to study effect of diet on cancer drugs. A groundbreaking clinical trial on whether diet could boost the effectiveness of cancer drugs is set to be launched by one of the world’s leading oncologists... | via The Guardian ow.ly/riLN30kVFzk... See MoreSee Less
Ibrutinib (Imbruvica) & venetoclax (Venclexta) in previously untreated patients with #CLL greatly reduced the risk of venetoclax-associated tumor-lysis syndrome and led to promising rates of undetectable minimal residual disease (MRD) | via ASCO ow.ly/IBFY30kUv1Y... See MoreSee Less
A REGIMEN COMBINING ibrutinib (Imbruvica) and venetoclax (Venclexta) in previously untreated patients with chronic lymphocytic leukemia (CLL) greatly reduced the risk of venetoclax-associated tumor-lysis syndrome and led to promising rates of undetectable minimal residual disease (MRD) in the phase....
Here #CLL expert Anthony Mato from Memorial Sloan Kettering Cancer Center discusses the use of #umbralisib for patients who are intolerant to #ibrutinib & other PI3K or BTK inhibitors | via VJHemOnc youtu.be/YCDv-dCT1PoIntolerance is the most common reason for discontinuing PI3K or BTK inhibitor drugs used for the treatment of chronic lymphocytic leukemia (CLL), and it has ... ... See MoreSee Less
This webinar on Car-T should be of interest to our CLL community.Register for the MMRF CAR T-Cell Therapy webinar on July 17th. This webinar takes a look at some of the different types of CAR T-cells and discusses how they have performed in clinical trials. Learn about the promise and the challenges of CAR T-cell therapy: ow.ly/WOyK30kOVHw... See MoreSee Less
When I was diagnosed, I had no choice but to jump into gear and start fighting my fight. I was presented with options and had to make decisions quickly. Then the routines of treatment started and focusing on pushing through until the next one. I thought all I had to do was get through treatment and....
Cancer immunotherapy 'could be safer' with natural killer cells The new approach uses natural killer (NK) cells obtained from human induced pluripotent stem cells (iPSCs) instead of patient-specific T cells | via Medical News Today ow.ly/tu4q30kPEZv... See MoreSee Less
A discussion about the Murano trial for #CLL patients had at #EHA23 between Deborah Sims and John Seymour | via Leukaemia Care youtu.be/8P3mZ0-8s2cA discussion about the MURANO trial from Deborah Sims and John Seymour. Filmed at EHA in 2018 for Leukaemia Care. For more information on CLL, head to www.le... ... See MoreSee Less